Improvement of chronic renal failure after introduction of mycophenolate mofetil and reduction of cyclosporine dose
G. Rábago (1), N. Manito (2), J. Palomo (3), J. M. Arizón (4), J. Delgado (5), L. Almenar (6), M. Crespo (7), E. Lage (8) and L. Pulpón (9)
(1) University of Navarra, Pamplona, Spain
(2) Hospital de Bellvitge, Spain
(3) Hospital Gregorio Marañón, Spain
(4) Hospital Reina Sofía, Córdoba, Spain
(5) Hospital 12 de Octubre, Madrid, Spain
(6) Hospital la Fe, Valencia, Spain
(7) Hospital Juan Canalejo, La Coruña, Spain
(8) Hospital Ntra. Sra del Rocío, Sevilla, Spain
(9) Clínica Puerta de Hierro, Madrid, Spain
Magazine: The Journal of Heart and Lung Transplantation
Date: Feb 1, 2001Cardiac Surgery [SP]
Chronic renal insufficiency remains a long-term complication in heart transplant patients (HT) clearly associated with the use of ciclosporine a (Csa).
The introduction of new immunosuppressive drugs like mycophenolate mofetil (MMF) allows us to decrease the dose of Csa and their nephrotoxic effects. We designs a prospective multicentric study where we include heart transplant patients treated with Csa over eighteen months and with renal insufficiency (creatinine . 1,4 mg/dl in two previous determination).
We introduce MMF and them decrease the dose of Csa keeping the trough levels under 100 ng/ml. Primary endpoint was renal function improvement and secondary endpoint were rejection episode, infection and metabolic disorders. Seventy-four patients (66 males and 8 females) were include in the study with a mean age of 59610 years. Mean time between HT and inclusion in the study were 5,8 years (range 1,5 to 12,6 years).
CITATION J Heart Lung Transplant. 2001 Feb;20(2):193
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.